Clinical trials: Leukemia-Lymphoma, open to volunteers
Mantle Cell Lymphoma, Follicular Lymphoma
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells…
- Conditions
- Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT04223765
- Testing
- CAR.k.28, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
This pilot study examines the safety and efficacy of anti-CD19 CAR T cells manufactured on-site in children and young adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission
- Trial name
- NCT05779930
- Testing
- CD19 specific Chimeric Antigen Receptor T Cell
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
Phase II Clinical Trial, Blinatumomab
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
- Conditions
- Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia
- Trial name
- NCT07178912
- Testing
- Blinatumomab, olverembatinib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoblastic Leukemia
Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients
Role of cbc indices in acute lymphoblastic leukemia patients to explore the prognostic role of them in prediction the response to induction chemotherapy
- Trial name
- NCT06746571
- Testing
- complete blood count
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Acute Lymphoid Leukemia
Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
This study is open-label, multi-center, prospective study, which targets childhood patients with relapsed acute lymphostatic leukemia including bone marrow recurrence.
- Trial name
- ReCALL (NCT05827549)
- Testing
- Reinduction(4weeks), Cosolodation 1st(3weeks), Consolidation 2nd(3weeks)
- Where
- 10 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Ho Joon Im
T-ALL
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
The planned trial offers treatment cohorts for patients with full cytologic relapse (R/R ALL - Cohort 1), as well as for patients with molecular failure/relapse (MRD+ ALL - Cohort 2).
- Trial name
- NCT06648889
- Testing
- Isatuximab
- Where
- 15 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Goethe University
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in…
- Trial name
- SYRUS (NCT06137118)
- Testing
- Surovatamig
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 255 people
- Sponsor
- AstraZeneca
Acute Lymphoblastic Leukemia
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- Trial name
- NCT07066397
- Testing
- ARM011, Fludarabine, Cyclophosphamide
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- TriArm Therapeutics (Taiwan) Limited
Precursor B-Cell Lymphoblastic Leukemia
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults.
- Trial name
- NCT06554626
- Testing
- Dexamethasone, Blinatumomab, Venetoclax
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
B-cell Malignancy, Chronic Lymphocytic Leukemia
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
- Conditions
- B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
- Trial name
- NCT05602363
- Testing
- Docirbrutinib
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Carna Biosciences, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
This is a phase 2, open-label, multicenter study evaluating the efficacy and safety of a fixed-duration combination of epcoritamab, venetoclax, and ibrutinib (EVI) in previously untreated patients with chronic lymphocytic…
- Trial name
- EVITA (NCT07738887)
- Testing
- Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab
- Where
- 29 sites in Belgium, France
- Volunteers
- 44 people
- Sponsor
- The Lymphoma Academic Research Organisation
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Digital Patient-Reported Assessment in Older Adults With Acute Leukemia
This pilot study will evaluate the feasibility of implementing a structured digital patient-reported assessment pathway in adults aged 65 years or older with acute leukemia at Hospital Universitario Central de Asturias, Oviedo…
- Trial name
- NCT07597590
- Testing
- Digital Patient-Reported Assessment Pathway
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundación para la Investigación Biosanitaria del Principado de Asturias
Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL
An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders
This follow-up study is designed to evaluate the long-term safety and effectiveness of a treatment called anti-CD19 CAR-T cell therapy in adults with certain B-cell blood cancers.
- Trial name
- NCT06721598
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- National Research Center for Hematology, Russia
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
The goal of this clinical trial is to study the efficacy of the tagraxofusp + venetoclax combination in treatment-naive blastic plasmacytoid dendritic cell neoplasm adult patients.
- Trial name
- TAGVEN (NCT07007052)
- Testing
- Venetoclax, Tagraxofusp
- Where
- 34 sites in France
- Volunteers
- 33 people
- Sponsor
- French Innovative Leukemia Organisation
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
- Conditions
- Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma
- Trial name
- NCT01137825
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease.
- Conditions
- T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT07220993
- Testing
- CD7.CAR/28zeta T Cells
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Not Having Achieved Remission
Determining the Mechanisms of Loss of CAR T Cell Persistence
A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells).
- Conditions
- Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, Adult
- Trial name
- CARPERS (NCT05809284)
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
This phase I trial tests the safety and effectiveness of pomalidomide after CD19 chimeric antigen receptor T-cell (CD19CART) therapy for the treatment of patients with CD19+ B-cell leukemias or lymphomas that have come back after…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT07532525
- Testing
- Biospecimen Collection, Pomalidomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan Rogel Cancer Center
T-Cell Leukemia/Lymphoma, Adult
Novel Therapeutic Approach for Human T-cell Malignancies
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
- Trial name
- NCT06600568
- Testing
- Translation analysis
- Where
- 2 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Acute Leukemia, Lymphoblastic Leukemia
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses.
- Conditions
- Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Trial name
- NCT06207123
- Testing
- LP-118, Ponatinib, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Chicago